Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Cash: 2019-2024

Historic Change in Cash for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to -$105.8 million.

  • Day One Biopharmaceuticals' Change in Cash fell 95.82% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$379.5 million, marking a year-over-year decrease of 308.99%. This contributed to the annual value of -$105.8 million for FY2024, which is 172.71% down from last year.
  • As of FY2024, Day One Biopharmaceuticals' Change in Cash stood at -$105.8 million, which was down 172.71% from $145.5 million recorded in FY2023.
  • Day One Biopharmaceuticals' Change in Cash's 5-year high stood at $240.6 million during FY2021, with a 5-year trough of -$199.0 million in FY2022.
  • Moreover, its 3-year median value for Change in Cash was -$105.8 million (2024), whereas its average is -$53.1 million.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 1,367.32% in 2021, then crashed by 182.74% in 2022.
  • Yearly analysis of 5 years shows Day One Biopharmaceuticals' Change in Cash stood at $16.4 million in 2020, then spiked by 1,367.32% to $240.6 million in 2021, then tumbled by 182.74% to -$199.0 million in 2022, then surged by 173.11% to $145.5 million in 2023, then slumped by 172.71% to -$105.8 million in 2024.